Fenugreek has been shown to have beneficial effects on various metabolic abnormalities associated with metabolic syndrome (MS). However, no clinical trials have evaluated its effect on all components of MS, insulin sensitivity, and insulin secretion. Therefore, the main objective of this study is to assess the effect of fenugreek seed administration versus placebo on the components of metabolic syndrome, insulin sensitivity, and insulin secretion.
Men and women between 30 and 60 years old.
Diagnosis of Metabolic Syndrome (MS) according to the International Diabetes Federation (IDF) criteria.
Fasting glucose ≥100 mg/dL or previous diagnosis of type 2 diabetes.
Systolic Blood Pressure ≥130 mmHg.
Voluntary withdrawal of informed consent.
Treatment adherence ≤80%.
Occurrence of a serious adverse event.
Loss to follow-up.